Trial · NCT04897880
A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT
NCT04897880, Phase 2, Terminated, Australian & New Zealand Children's Haematology/Oncology Group
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT. Trials, record NCT04897880. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04897880
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT
- NCT number
- NCT04897880
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 25 participants, actual
- Lead sponsor
- Australian & New Zealand Children's Haematology/Oncology Group
- Conditions
- Rhabdoid Tumor, Atypical Teratoid/Rhabdoid Tumor, Malignant Rhabdoid Tumor, Recurrent Brain Tumor, Childhood
- Interventions
- Panobinostat
- First posted
- 2021-05-24
- Last updated
- 2025-02-24
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Event free survival | Up to 2 years after study enrolment | Estimated 2-year Event free survival (EFS). EFS is calculated as the time from study enrolment to first documented disease progression, relapse or second malignancy, or death from any cause. |
| Primary | Overall Survival | Up to 2 years after study enrolment | Estimated 2-year Overall Survival (OS). OS is calculated as the time from study enrolment to death from any cause. |
| Primary | Safety: Adverse events summarised by grade and type | From 1 week to 12 months after intervention commencement | Graded and defined by CTCAE Version 4 |
| Secondary | Efficacy as measured by Clinical Benefit Rate | At 6 and 12 months after intervention commencement | Clinical benefit rate as the percentage of patients with stable disease or better using MRI/CT imaging). Stable disease is defined as MRT/ATRT/Osteosarcoma with CR/PR/MR/SD/ overall response. Neuroblastoma with CR/PR/SD or Non-CR/Non-PD overall response. |
| Other | Comparison between trial participants and historical control data | OS and EFS survival up to 2 years after study enrolment | Comparing overall and event free survival for ATRT/MRT patients to historical data. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04897880
GET https://conductscience.org/api/trials/v1/NCT04897880/registered